154 related articles for article (PubMed ID: 34031321)
1. Opioid use disorder and COVID-19: Implications for policy and practice.
Mitchell M; Shee K; Champlin K; Essary AC; Evans M
JAAPA; 2021 Jun; 34(6):1-4. PubMed ID: 34031321
[TBL] [Abstract][Full Text] [Related]
2. Using buprenorphine to treat patients with opioid use disorder.
Radi JK; Fogarty KJ; Lagerwey MD
JAAPA; 2019 Oct; 32(10):30-35. PubMed ID: 31513035
[TBL] [Abstract][Full Text] [Related]
3. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
4. In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants.
Barnett ML; Lee D; Frank RG
Health Aff (Millwood); 2019 Dec; 38(12):2048-2056. PubMed ID: 31794302
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
[TBL] [Abstract][Full Text] [Related]
6. Nurse Practitioner Prescriptive Authority for Buprenorphine: From DATA 2000 to CARA 2016.
Fornili KS; Fogger SA
J Addict Nurs; 2017; 28(1):43-48. PubMed ID: 28252511
[TBL] [Abstract][Full Text] [Related]
7. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
8. Nurse Practitioner and Physician Assistant Waivers to Prescribe Buprenorphine and State Scope of Practice Restrictions.
Spetz J; Toretsky C; Chapman S; Phoenix B; Tierney M
JAMA; 2019 Apr; 321(14):1407-1408. PubMed ID: 30964519
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
Jones CM; McCance-Katz EF
Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
[TBL] [Abstract][Full Text] [Related]
10. Expanding access to nurse-managed medication for opioid use disorder.
Cos TA; Starbird LE; Lee H; Chun B; Gonnella K; Bird J; Livsey K; Bastos S; O'Brien M; Clark I; Jenkins D; Tavolaro-Ryley L
Nurs Outlook; 2021; 69(5):848-855. PubMed ID: 33992445
[TBL] [Abstract][Full Text] [Related]
11. Nurse practitioner and physician assistant interest in prescribing buprenorphine.
Roose RJ; Kunins HV; Sohler NL; Elam RT; Cunningham CO
J Subst Abuse Treat; 2008 Jun; 34(4):456-9. PubMed ID: 17664052
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 Could Change the Way We Respond to the Opioid Crisis-for the Better.
Bao Y; Williams AR; Schackman BR
Psychiatr Serv; 2020 Dec; 71(12):1214-1215. PubMed ID: 32781928
[No Abstract] [Full Text] [Related]
13. Federal Impacts on Buprenorphine Prescribing in Washington State, 2012 to 2022.
Xiong F; Jetson J; Park C; Delcher C
Am J Public Health; 2024 Jul; 114(7):696-704. PubMed ID: 38696736
[No Abstract] [Full Text] [Related]
14. The role of NPs in medication-assisted treatment for opioid use disorder.
Cotton BP; Ferszt GG
Nurse Pract; 2018 May; 43(5):8. PubMed ID: 29668514
[No Abstract] [Full Text] [Related]
15. Projected Contributions of Nurse Practitioners and Physicians Assistant to Buprenorphine Treatment Services for Opioid Use Disorder in Rural Areas.
Andrilla CHA; Patterson DG; Moore TE; Coulthard C; Larson EH
Med Care Res Rev; 2020 Apr; 77(2):208-216. PubMed ID: 30089426
[TBL] [Abstract][Full Text] [Related]
16. A Primary Care Response to COVID-19 for Patients with an Opioid Use Disorder.
Wilson CG; Ramage M; Fagan EB
J Rural Health; 2021 Jan; 37(1):169-171. PubMed ID: 32277732
[No Abstract] [Full Text] [Related]
17. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
[TBL] [Abstract][Full Text] [Related]
18. Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.
Livingston NA; Ameral V; Banducci AN; Weisberg RB
J Subst Abuse Treat; 2021 Mar; 122():108222. PubMed ID: 33303255
[TBL] [Abstract][Full Text] [Related]
19. Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.
Andraka-Christou B; Page C; Schoebel V; Buche J; Haffajee RL
Addict Sci Clin Pract; 2022 Aug; 17(1):43. PubMed ID: 35945636
[TBL] [Abstract][Full Text] [Related]
20. When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access.
Cooper HLF; Cloud DH; Young AM; Freeman PR
N Engl J Med; 2020 Aug; 383(8):703-705. PubMed ID: 32813945
[No Abstract] [Full Text] [Related]
[Next] [New Search]
